Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy : A patient series. / Lund, Tamara; Thomsen, Simon Francis.

I: Dermatologic Therapy, Bind 30, Nr. 3, e12454, 05.2017.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Lund, T & Thomsen, SF 2017, 'Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series', Dermatologic Therapy, bind 30, nr. 3, e12454. https://doi.org/10.1111/dth.12454

APA

Lund, T., & Thomsen, S. F. (2017). Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. Dermatologic Therapy, 30(3), [e12454]. https://doi.org/10.1111/dth.12454

Vancouver

Lund T, Thomsen SF. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. Dermatologic Therapy. 2017 maj;30(3). e12454. https://doi.org/10.1111/dth.12454

Author

Lund, Tamara ; Thomsen, Simon Francis. / Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy : A patient series. I: Dermatologic Therapy. 2017 ; Bind 30, Nr. 3.

Bibtex

@article{54685a329c0e453ea0e7d511869ff591,
title = "Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series",
abstract = "From 2002 to 2016 a total of seven women with severe refractory psoriasis were exposed to the TNF-inhibitors infliximab and adalimumab or to the IL12/23 inhibitor ustekinumab during one or more pregnancies. Maternal, fetal or teratogenic toxicity were not detected during pregnancy and puerperium. All pregnancies were uneventful and resulted in delivery of 10 healthy children in total, one of the women is due February 2017. Postpartum, five of the women were lactating, but none of the women or newborns developed adverse reactions. Data on safety of treatment during breastfeeding are sparse, but so far appears to be safe due to the lack of absorption across the gastrointestinal lining. Currently biological therapy with either TNF-inhibitors or ustekinumab is not recommended during pregnancy, however in selected women with severe psoriasis these treatment modalities may be considered.",
keywords = "biologics, inflammatory disorders, pharmacology, psoriasis, therapy-systemic",
author = "Tamara Lund and Thomsen, {Simon Francis}",
year = "2017",
month = "5",
doi = "10.1111/dth.12454",
language = "English",
volume = "30",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy

T2 - A patient series

AU - Lund, Tamara

AU - Thomsen, Simon Francis

PY - 2017/5

Y1 - 2017/5

N2 - From 2002 to 2016 a total of seven women with severe refractory psoriasis were exposed to the TNF-inhibitors infliximab and adalimumab or to the IL12/23 inhibitor ustekinumab during one or more pregnancies. Maternal, fetal or teratogenic toxicity were not detected during pregnancy and puerperium. All pregnancies were uneventful and resulted in delivery of 10 healthy children in total, one of the women is due February 2017. Postpartum, five of the women were lactating, but none of the women or newborns developed adverse reactions. Data on safety of treatment during breastfeeding are sparse, but so far appears to be safe due to the lack of absorption across the gastrointestinal lining. Currently biological therapy with either TNF-inhibitors or ustekinumab is not recommended during pregnancy, however in selected women with severe psoriasis these treatment modalities may be considered.

AB - From 2002 to 2016 a total of seven women with severe refractory psoriasis were exposed to the TNF-inhibitors infliximab and adalimumab or to the IL12/23 inhibitor ustekinumab during one or more pregnancies. Maternal, fetal or teratogenic toxicity were not detected during pregnancy and puerperium. All pregnancies were uneventful and resulted in delivery of 10 healthy children in total, one of the women is due February 2017. Postpartum, five of the women were lactating, but none of the women or newborns developed adverse reactions. Data on safety of treatment during breastfeeding are sparse, but so far appears to be safe due to the lack of absorption across the gastrointestinal lining. Currently biological therapy with either TNF-inhibitors or ustekinumab is not recommended during pregnancy, however in selected women with severe psoriasis these treatment modalities may be considered.

KW - biologics

KW - inflammatory disorders

KW - pharmacology

KW - psoriasis

KW - therapy-systemic

U2 - 10.1111/dth.12454

DO - 10.1111/dth.12454

M3 - Journal article

C2 - 28071837

AN - SCOPUS:85020073354

VL - 30

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

IS - 3

M1 - e12454

ER -

ID: 196441549